3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Motor Activity
2
Breast Neoplasms
2
Weight Loss
1
Uterine Cervical Dysplasia
1
Polycystic Ovary Syndrome
1
Papillomavirus Infections
1
Obesity
1
Insulin Resistance
1
Infertility, Female
1
Infections
1
Cognitive Dysfunction
1
Interventions
Trimethoprim, Sulfamethoxazole Drug Combination
9
Ciprofloxacin
7
gamma-Globulins
3
Voriconazole
3
Fluconazole
3
Daptomycin
3
Antibiotic Prophylaxis
3
Amoxicillin-Potassium Clavulanate Combination
3
Whole-Body Irradiation
2
Vancomycin
2
Trimethoprim
2
Sulfamethoxazole
2
Saline Solution
2
Ribavirin
2
Peripheral Blood Stem Cell Transplantation
2
Pentetic Acid
2
Melphalan
2
Itraconazole
2
Immunoglobulins, Intravenous
2
Fosfomycin
2
Ethanol
2
Cyclophosphamide
2
Cefazolin
2
Caspofungin
2
ziprasidone
1
tocilizumab
1
telavancin
1
telaprevir
1
talquetamab
1
soybean oil, phospholipid emulsion
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Infections
×
lime
×
Clear all
NCT02346227
2018-10-12
KINVAV
Universiteit Antwerpen
Phase 3
Completed
327 enrolled